Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment.

ABSTRACT: Quantitative hepatitis B serum antigen (HBsAg) level <100 IU/mL has been proposed as one of the key criteria for partial cure for chronic hepatitis B (CHB) and as an important threshold for stopping nucleos(t)ide analogues (NAs) with a finite therapeutic strategy. We investigated the incidence and associated factors of HBsAg<100 IU/mL in hepatitis B e antigen (HBeAg)-negative CHB patients initiating NAs therapy. A total of 996 HBeAg-negative CHB patients with baseline HBsAg>100 IU/mL initiating first-line NAs treatment from five hospitals in China were retrospectively included. Cumulative incidence and associated factors of HBsAg<100 IU/mL were assessed using Kaplan-Meier and Cox regression analyses, respectively. During a median follow-up of 28.8 months, 69 patients (6.9%) achieved HBsAg<

SUBMITTER: Wang J 

PROVIDER: S-EPMC12444948 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature